This German Biotech's $6.4M Seed Round Targets a Silent Heart Disease Epidemic

Jan de Vries · 2026-08-28

A fresh European biotech startup has just stepped into the ring, and it's aiming its science at a massive, often overlooked health challenge. Revier Therapeutics, based in the historic German city of Heidelberg, has officially launched with a $6.4 million Seed financing round. That's right, they've secured over six million dollars to tackle cardiometabolic diseases—a complex cluster of conditions that includes heart failure and atherosclerosis, which affect millions globally. It's a significant vote of confidence from a heavyweight investor group. The round was spearheaded by the KHAN Technology Transfer Fund II, with key participation from High-Tech Gründerfonds (HTGF), VORNvc, and private investors via Revier Invest Heidelberg. This coalition isn't just writing checks; they're betting on a novel scientific approach that could reshape patient care. ### The Unmet Need Driving Their Mission So, what's the big deal? Despite all our medical advances, a huge gap remains. Prof. Eva van Rooij, PhD, the company's co-founder and CEO, puts it plainly. She says millions of patients living with specific heart conditions—like HFpEF (heart failure with preserved ejection fraction) and ASCVD (atherosclerotic cardiovascular disease)—still don't have great, targeted treatment options. It's a silent epidemic where the current tools just aren't enough. "We believe the next generation of medicines needs to go deeper," van Rooij explains. "They have to address the underlying disease-driving biology, not just the symptoms. That's the only way to deliver solutions that are both impactful and lasting for patients." Their entire mission is built on translating a specific piece of science—class IIa HDAC inhibition—into real therapies that can quickly move from the lab to the clinic. ### The Science: A More Precise Target Here's where it gets technical, but let's break it down simply. HDACs are enzymes in the body that play a role in several serious diseases. Earlier attempts to target them were a bit like using a sledgehammer—they broadly inhibited multiple classes, which often led to nasty side effects that limited how much medicine a patient could tolerate. Revier claims it's built the first therapeutic approach that selectively targets just the class IIa HDACs for cardiometabolic diseases. Think of it as a precision scalpel instead of that sledgehammer. Their small-molecule drugs are designed to be taken orally and are engineered to inhibit only the harmful enzymatic activity, while carefully preserving healthy biological function. Prof. Johannes Backs, MD, the scientific founder, highlights this precision. "Our first-in-class molecules are selective," he says. "They're designed to be therapeutically effective but with a much better safety profile. That's the key." - **The Problem:** Broad HDAC inhibitors cause dose-limiting side effects. - **Revier's Solution:** Selective targeting of only class IIa HDACs. - **The Goal:** Effective treatment that patients can tolerate long-term. ### Why Investors Are Betting on This Team The investor confidence isn't just about the science; it's about the people executing the vision. Michael Hamacher, PhD, from the lead investor KHAN, pointed to the "exceptional leadership team and deep scientific expertise" as a major reason for backing the company. He believes Revier's strategy has the unique potential to "unlock the therapeutic promise of HDAC biology" and actually deliver disease-modifying medicines that provide durable benefits. So, what's next for this well-funded startup? The $6.4 million capital injection is earmarked for advancing their preclinical pipeline. They'll focus on their lead program for HFpEF and a second program for ASCVD. The funds will also help them build out their operational, scientific, and clinical teams—essentially, turning this promising research into a fully-fledged, clinical-stage company. For patients waiting on better options, that progress can't come soon enough.